MeiraGTx Misses by $0.07 per Share as Revenue Falls Short at $4.81 Million

MeiraGTx Holdings plc (NASDAQ:MGTX) reported a quarterly loss of $0.53 per share on Thursday, missing the consensus estimate of a $0.46 loss by $0.07. Revenue of $4.81 million came in well below the $6.95 million that analysts expected. The market rendered its verdict promptly: the shares fell $0.89, or 9.2 percent, to $8.79.

Volume told its own story. Some 1,363,121 shares changed hands on Thursday, more than double the average of 620,787. Evidently, a miss of this size attracts attention.

What do the balance-sheet metrics show?

The gene-therapy developer posted a return on equity (net income as a percentage of shareholder equity) of 283.85 percent and a net margin (net income as a percentage of revenue) of 19.87 percent. Curious figures for a clinical-stage firm, but the accounting permits it.

The balance sheet itself looks sturdy, at least on liquidity:

• Debt-to-equity ratio: 0.46
• Quick ratio (liquid assets minus inventory over current liabilities): 3.76
• Current ratio: 3.76

The shares have traded between a 12-month low of $6.62 and a 12-month high of $15.35. The 50-day moving average sits at $10.81 and the 200-day at $10.36, both comfortably above Thursday's close of $8.79. The market capitalization stands at $844.19 million, with a price-to-earnings ratio of 12.38 and a beta (sensitivity to market moves) of 1.09.

How did analysts respond?

The sell side has been busy. Five research actions stand out:

• Wall Street Zen raised the stock from "hold" to "buy" on Saturday, October 24.
• Royal Bank of Canada lifted its target from $26.00 to $27.00 with an "outperform" rating on Friday, August 14.
• Weiss Ratings moved from "hold (c)" to "hold (c+)" on Thursday, October 8.
• Goldman Sachs initiated coverage on Thursday, September 24, with a "neutral" rating and a $16.00 target.
• Zacks Research downgraded the shares from "strong-buy" to "hold" on Friday, September 11.

The aggregate view is mildly constructive. Five analysts rate the stock a Buy and three a Hold, producing a consensus rating of "Moderate Buy" and a consensus price target of $24.00, according to MarketBeat. A $24 target against an $8.79 close is a confident forecast. Confidence is cheap in research notes.

What are insiders doing?

CEO Alexandria Forbes sold 62,000 shares on Tuesday, August 18, at an average price of $13.86, for a total of $859,320.00. The sale reduced her position by 4.47 percent; she retains 1,325,695 shares worth approximately $18,374,132.70.

CFO Richard Giroux followed suit on Tuesday, October 20, selling 56,000 shares at $9.95 for $557,200.00. His stake fell 6.16 percent, leaving him with 852,530 shares valued at roughly $8,482,673.50. Both sales were executed under pre-arranged Rule 10b5-1 trading plans (automatic sell schedules set in advance to avoid insider-trading concerns) and disclosed in filings with the Securities and Exchange Commission.

In aggregate, insiders sold 145,659 shares valued at $1,710,812 over the last three months. Corporate insiders own 7.40 percent of the company's stock.

What does the company actually do?

MeiraGTx Holdings plc, founded in 2015 and operating in the United States and the United Kingdom, develops gene therapies for serious diseases with limited treatment options. Its research uses adeno-associated virus (AAV) vectors — engineered viruses that deliver genetic material to target cells — across programs covering inherited retinal diseases, neurological conditions and salivary gland dysfunction. The company also builds manufacturing capabilities intended to support gene-therapy production.

The near-term arithmetic is unforgiving: a $0.07 miss, $2.14 million of revenue shortfall, and a share price 9.2 percent lower. The consensus target of $24.00 suggests the sell side expects considerably better quarters ahead. The insiders, one notes, have been selling into that optimism.